lucas lung cancer blood screening canary islands

New blood test to screen for lung cancer in Canary Islands

Compiled with the help of artificial intelligence, based on Spanish-language information. Source below the article.

Lung cancer overtakes cardiovascular disease as a cause of death

Lung cancer has become a public health problem of the first magnitude in the Canary Islands, having overtaken cardiovascular disease as a cause of death over the past two years. The great tragedy of this disease lies in its late diagnosis, since in its early stages it is asymptomatic. While other common tumours have mass, well-established screening programmes — such as mammography for breast cancer or the faecal occult blood test for colon cancer — lung cancer lacks a truly viable system, because the conventional screening test is a low-dose CT scan, whose direct application to the asymptomatic population is unworkable in the Islands owing to the saturation of radiodiagnosis services, which are fully stretched by urgent care and the staging of patients who have already been diagnosed.

Lucas: a blood test to filter patients before the scanner

To tackle this problem in the Canary Islands, Lucas has been launched — an acronym for LUng CAncer Screening: a clinical project recently awarded a grant by the Fundación Mapfre Canarias that evaluates a panel of eight tumour markers in blood, alongside kidney and liver function, in order to calculate each individual’s risk by means of an algorithm before a scan is carried out. This would — in future — make it possible to act as a filter from primary care and thus avoid overloading the radiodiagnosis services of hospitals across the Canary Islands.

María Cecilia Martín, a doctor at Hospital Nuestra Señora de la Candelaria and director of the project, explains that Lucas was created with the aim of replicating the early-detection philosophy used for other tumour pathologies — such as the faecal occult blood test in the case of colon cancer — but adapted to lung cancer, creating an analytical blood filter prior to radiology.

Eight tumour markers combined with kidney and liver function

The doctor explains that, biologically, lung tumours show high histological heterogeneity — adenocarcinomas, small-cell carcinomas and others — unlike other monospecific cancers such as prostate cancer. “To be able to cover all those different types of cells,” she says, the project measures “a battery of eight different tumour markers”, combined with kidney and liver function tests. These latter determinations are crucial, since failures in the clearance of these tests can artificially raise the concentration of certain markers in the blood “and generate false positives”. A computer algorithm adjusts blood levels to each individual’s metabolic and biological profile, issuing a three-tier risk stratification — low, moderate or high — that determines who should be referred for a CT scan.

A 100% success rate in hospital patients with suspicious nodules

Although blood analysis has a theoretically lower sensitivity than direct visual inspection, the marker algorithm has already been tested in the hospital setting in patients admitted with suspicious lung nodules. In that clinical group, Martín highlights that the tool not only helped to point towards the tumour lineage — that is, distinguishing between adenocarcinoma and small-cell — but also achieved a 100% success rate. “On many occasions the nodules were very tiny, or could not even be seen, but the algorithm was already alerting us that there was indeed a cancer. That is where the idea of testing it as a screening tool came from,” the doctor asserts.

Funding secured and first patients from December

The project has obtained funding through a grant from the Fundación Mapfre Canarias, which will cover the costs of the analytical determinations and the confirming scans. At present, the research team is drawing up the clinical report for evaluation by the hospital’s Ethics and Research Committee, with the intention of submitting it at the beginning of November and starting the selection of the first patients in December or, at the latest, the beginning of January. The initial sample will consist of 100 patients recruited from the dedicated Smoking and Chronic Obstructive Pulmonary Disease (COPD) clinics at Hospital Nuestra Señora de la Candelaria and Hospital del Sur.

“Both the Smoking and the COPD clinics provide the group of patients with a high percentage risk of developing lung cancer,” Martín explains.

Primary care doctors as the gateway to the test

The care model envisaged places primary care doctors as the key prescribers of the test. As the professionals with the greatest knowledge of the patient’s history, such as their smoking habit or previous conditions, the project director argues that they are ideally placed to carry out the first filter in the asymptomatic population. As for its technical viability, the algorithm is hosted in the cloud — online — and the battery of eight tumour markers is already routinely carried out in the laboratories of the four main public hospitals in the Canary Islands under the Canary Islands Health Service. If the pilot results are favourable, the programme could be implemented across the whole of the Archipelago’s health system without the need for investment in new analytical infrastructure.

Blood testing could lower the starting age to 40

At present, international guidelines for lung cancer screening by CT scan set the entry profile at people aged 50 and over with a high cumulative tobacco consumption — a pack-year index of 20 or more. This age limit is due to the biological risk of repeated ionising radiation from the scanner, according to Martín, which can induce other tumours in younger people. However, by using a conventional blood draw, Lucas removes the radiological factor. Given that the average age of onset of lung cancer has stood at 45, blood analysis opens the door to beginning early detection in the 40 to 45 age bracket.

Source

Scroll to Top